Novavax, Inc. (NASDAQ:NVAX) shares are trading lower by 14.20% at $50.14. Bank of America's Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35. Nuvaxovid is likely to underperform the longer-term consensus estimates, Stranahan said in the initiation note... Read More
Stocks have also been highly volatile following the Federal Reserve’s recent 50 basis point rate hike, which has weighed on the Nasdaq heavily.
